Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda has registered a marketing authorization application (MAA) of its Dymista in Europe.
Subscribe to our email newsletter
The MAA includes the efficacy and safety data of several studies involving over 4,000 patients, and also includes a long-term safety study with more than 600 patients.
Dymista is formulated with azelastine hydrochloride and fluticasone propionate and is used as a nasal spray formulation to treat moderate to severe allergic rhinitis and rhinoconjuctivitis.